These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 21841751

  • 1. Activity of oxaliplatin plus capecitabine (CapeOx) with lapatinib for metastatic colorectal cancer: results from two patients treated on a clinical study.
    Mohammed TA, Dennie T, Holen KD.
    Clin Adv Hematol Oncol; 2011 Jun; 9(6):492-500. PubMed ID: 21841751
    [No Abstract] [Full Text] [Related]

  • 2. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study.
    Hochster HS, Hart LL, Ramanathan RK, Childs BH, Hainsworth JD, Cohn AL, Wong L, Fehrenbacher L, Abubakr Y, Saif MW, Schwartzberg L, Hedrick E.
    J Clin Oncol; 2008 Jul 20; 26(21):3523-9. PubMed ID: 18640933
    [Abstract] [Full Text] [Related]

  • 3. Capecitabine and oxaliplatin (XELOX) as first-line treatment for patients with metastatic colorectal cancer.
    Karacetin D, Yalcin B, Okten B, Ozturk S, Maral O, Incekara O.
    J BUON; 2009 Jul 20; 14(4):605-8. PubMed ID: 20148449
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Alternating XELFOX and XELFIRI in patients with metastatic colorectal cancer.
    Recchia F, Candeloro G, Necozione S, Bratta M, Bisegna R, Rea S.
    Am J Clin Oncol; 2008 Aug 20; 31(4):323-8. PubMed ID: 18845989
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The combination of capecitabine and oxaliplatin in metastatic colorectal cancer.
    Clin Colorectal Cancer; 2003 Feb 20; 2(4):205-9. PubMed ID: 12620138
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A phase I study of capecitabine, oxaliplatin, and lapatinib in metastatic or advanced solid tumors.
    Dennie TW, Fleming RA, Bowen CJ, Dar MM, Alberti D, Oliver K, Loconte N, Mulkerin D, Holen KD.
    Clin Colorectal Cancer; 2011 Mar 01; 10(1):57-62. PubMed ID: 21609937
    [Abstract] [Full Text] [Related]

  • 11. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group.
    Porschen R, Arkenau HT, Kubicka S, Greil R, Seufferlein T, Freier W, Kretzschmar A, Graeven U, Grothey A, Hinke A, Schmiegel W, Schmoll HJ, AIO Colorectal Study Group.
    J Clin Oncol; 2007 Sep 20; 25(27):4217-23. PubMed ID: 17548840
    [Abstract] [Full Text] [Related]

  • 12. Thymidine phosphorylase expression in metastatic sites is predictive for response in patients with colorectal cancer treated with continuous oral capecitabine and biweekly oxaliplatin.
    Petrioli R, Bargagli G, Lazzi S, Pascucci A, Francini E, Bellan C, Conca R, Martellucci I, Fiaschi AI, Lorenzi B, Francini G, Multidisciplinary Oncology Group in Gastrointestinal Tumors.
    Anticancer Drugs; 2010 Mar 20; 21(3):313-9. PubMed ID: 20016369
    [Abstract] [Full Text] [Related]

  • 13. Phase II study of short-course capecitabine plus oxaliplatin (XELOX) followed by maintenance capecitabine in advanced colorectal cancer: XelQuali study.
    Waddell T, Gollins S, Soe W, Valle J, Allen J, Bentley D, Morris J, Lloyd A, Swindell R, Taylor MB, Saunders MP.
    Cancer Chemother Pharmacol; 2011 May 20; 67(5):1111-7. PubMed ID: 20676676
    [Abstract] [Full Text] [Related]

  • 14. Patients with locally advanced and metastatic colorectal cancer treated with capecitabine versus 5-fluorouracil as monotherapy or combination therapy with oxaliplatin: a cost comparison.
    Chu E, Schulman KL, McKenna EF, Cartwright T.
    Clin Colorectal Cancer; 2010 Oct 20; 9(4):229-37. PubMed ID: 20920995
    [Abstract] [Full Text] [Related]

  • 15. Integrating oxaliplatin and capecitabine in adjuvant therapy of high-risk colorectal cancer.
    Maung K.
    Clin Colorectal Cancer; 2003 Nov 20; 3(3):150-3. PubMed ID: 14706173
    [No Abstract] [Full Text] [Related]

  • 16. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer.
    Cassidy J, Tabernero J, Twelves C, Brunet R, Butts C, Conroy T, Debraud F, Figer A, Grossmann J, Sawada N, Schöffski P, Sobrero A, Van Cutsem E, Díaz-Rubio E.
    J Clin Oncol; 2004 Jun 01; 22(11):2084-91. PubMed ID: 15169795
    [Abstract] [Full Text] [Related]

  • 17. Should capecitabine replace infusional fluorouracil and leucovorin when combined with oxaliplatin in metastatic colorectal cancer?
    Mayer RJ.
    J Clin Oncol; 2007 Sep 20; 25(27):4165-7. PubMed ID: 17709796
    [No Abstract] [Full Text] [Related]

  • 18. Capecitabine plus oxaliplatin for the treatment of colorectal cancer.
    Carrato A, Gallego-Plazas J, Guillén-Ponce C.
    Expert Rev Anticancer Ther; 2008 Feb 20; 8(2):161-74. PubMed ID: 18279056
    [Abstract] [Full Text] [Related]

  • 19. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108.
    Comella P, Natale D, Farris A, Gambardella A, Maiorino L, Massidda B, Casaretti R, Tafuto S, Lorusso V, Leo S, Cannone M.
    Cancer; 2005 Jul 15; 104(2):282-9. PubMed ID: 15948167
    [Abstract] [Full Text] [Related]

  • 20. Biweekly oxaliplatin combined with oral capecitabine (OXXEL regimen) as first-line treatment of metastatic colorectal cancer patients: a Southern Italy Cooperative Oncology Group phase II study.
    Comella P, Massidda B, Palmeri S, Farris A, Lucia LD, Natale D, Maiorino L, Tafuto S, Cataldis GD, Casaretti R.
    Cancer Chemother Pharmacol; 2005 Nov 15; 56(5):481-6. PubMed ID: 15902461
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.